Skip to content

The Effects of Blackcurrant Supplementation on Eye Health

The Effects of Blackcurrant Supplementation on Eye Health: a Randomized, Double Blind, Placebo Controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04775654
Enrollment
57
Registered
2021-03-01
Start date
2021-03-01
Completion date
2021-12-31
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Strain, Eye Fatigue

Keywords

black currant, blackcurrant, Ribes nigrum, digital eye fatigue, eye health, computer vision syndrome, dietary supplement

Brief summary

The purpose of this study is to evaluate the potential for supplementation with black currant to support eye health among otherwise healthy adult women who spend 6+ hours per day using digital screens.

Detailed description

Women who are informed about the study and provide informed consent will be randomized to one of two groups: supplement and placebo. Group assignment will be a 1:1 ratio to supplement (455mg of blackcurrant standardized to 50mg anthocyanins in 2 capsules/day) or placebo (2 capsules/day). Outcomes will be assessed at baseline and again on day 70.

Interventions

DIETARY_SUPPLEMENTBlackcurrant

Two capsules containing 455mg of CurrantCraft 11% black currant extract.

OTHERPlacebo

Two capsules containing an inert material.

Sponsors

Artemis International
CollaboratorUNKNOWN
Nutraceuticals Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participants and the individuals providing informed consent are masked.

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Female * Age 30-60 * Lives in the United States * Employed full time in an online work environment OR enrolled full time in an online learning environment (average of 6+ hours per day) * Ability to understand study instructions * Ability to provide informed consent * Residence within 100 miles of the study center

Exclusion criteria

* Low blood pressure * Uncontrolled hypertension (i.e. systolic/diastolic blood pressure \> 140/90) * Uncontrolled diabetes (i.e. fasting blood glucose \>180mg/dl) * Any blood clotting disorder * Ocular disease * Best corrected visual acuity \<20/30 * Cataracts * Renal disease * Active hepatitis or cirrhosis * Acute or chronic infectious disease * Pregnant * Breastfeeding * Currently trying to conceive * Surgical or other invasive procedure planned within the intervention period

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in ocular discomfort on day 70.Baseline and day 70The Ocular Discomfort scale is a validated self reported instrument assessing ocular discomfort symptoms. The scale contains 6 domains with a combination of likert scale (ranging from 1-7) and dichotomous (yes/no) questions. Higher scores indicate greater visual fatigue.
Change from baseline in visual fatigue on day 70.Baseline and day 70The Visual Fatigue scale is a validated self reported instrument assessing visual fatigue symptoms. It is a 6-question scale which asks about immediate symptoms (such as dry eyes). Participants rank their symptoms on a likert scale scored from 1-7, with higher scores indicating more severe symptoms.
Change from baseline in computer vision symptoms on day 70.Baseline and day 70The Computer Vision Symptom scale is a validated self reported instrument assessing computer vision symptoms. The scale measures 17 symptom domains, with scores ranging from 1-4 to 1-7. On each domain, higher scores indicate greater severity.
Change from baseline in symptoms of computer vision syndrome on day 70.Baseline and day 70The Computer Vision Syndrome Questionnaire is a validated self reported instrument assessing computer vision symptoms. The scale measures the presence or absence of 16 symptoms producing scores from 0-16. Higher scores indicate more symptoms.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026